FIELD: biochemistry.
SUBSTANCE: invention relates to a procoagulant bispecific antibody that specifically binds FIX and FX. Also the following is disclosed: a pharmaceutical composition and a medicinal product containing the said antibody for the treatment of hemophilia A.
EFFECT: invention makes it possible to effectively treat hemophilia A.
12 cl, 4 dwg, 17 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
ADVANCED PROCOAGULANT ANTIBODIES | 2019 |
|
RU2810748C2 |
ANTIBODY WHICH IS CAPABLE OF NEUTRALIZING A SUBSTANCE HAVING AN ACTIVITY OF AN ALTERNATIVE COAGULATION FACTOR FUNCTION VIII (FVIII) | 2015 |
|
RU2737145C2 |
METHOD FOR MEASURING REACTIVITY OF FVIII | 2015 |
|
RU2752595C2 |
BISPECIFIC ANTIBODY HAVING HIGH ACTIVITY, ALTERNATIVE FUNCTION OF COFACTOR FVIII | 2017 |
|
RU2821642C2 |
ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
CD131-BINDING PROTEINS AND THEIR APPLICATIONS | 2016 |
|
RU2773927C2 |
ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
Authors
Dates
2023-12-21—Published
2018-02-01—Filed